Mitophagy impairment in neurodegenerative diseases: Pathogenesis and therapeutic interventions.

Alzheimer disease Amyotrophic lateral sclerosis Huntington diseases Mitochondria Mitophagy Neurodegenerative diseases Parkinson disease

Journal

Mitochondrion
ISSN: 1872-8278
Titre abrégé: Mitochondrion
Pays: Netherlands
ID NLM: 100968751

Informations de publication

Date de publication:
03 2021
Historique:
received: 31 07 2020
revised: 23 10 2020
accepted: 14 01 2021
pubmed: 22 1 2021
medline: 3 11 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

Neurons are specialized cells, requiring a lot of energy for its proper functioning. Mitochondria are the key cellular organelles and produce most of the energy in the form of ATP, required for all the crucial functions of neurons. Hence, the regulation of mitochondrial biogenesis and quality control is important for maintaining neuronal health. As a part of mitochondrial quality control, the aged and damaged mitochondria are removed through a selective mode of autophagy called mitophagy. However, in different pathological conditions, this process is impaired in neuronal cells and lead to a variety of neurodegenerative disease (NDD). Various studies indicate that specific protein aggregates, the characteristics of different NDDs, affect this process of mitophagy, adding to the severity and progression of diseases. Though, the detailed process of this association is yet to be explored. In light of the significant role of impaired mitophagy in NDDs, further studies have also investigated a large number of therapeutic strategies to target mitophagy in these diseases. Our current review summarizes the abnormalities in different mitophagy pathways and their association with different NDDs. We have also elaborated upon various novel therapeutic strategies and their limitations to enhance mitophagy in NDDs that may help in the management of symptoms and increasing the life expectancy of NDD patients. Thus, our study provides an overview of mitophagy in NDDs and emphasizes the need to elucidate the mechanism of impaired mitophagy prevalent across different NDDs in future research. This will help designing better treatment options with high efficacy and specificity.

Identifiants

pubmed: 33476770
pii: S1567-7249(21)00001-5
doi: 10.1016/j.mito.2021.01.001
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

270-293

Informations de copyright

Copyright © 2021 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Auteurs

Shalini Mani (S)

Department of Biotechnology, Centre for Emerging Disease, Jaypee Institute of Information Technology, Noida, India. Electronic address: Shalini.mani@jiit.ac.in.

Geeta Swargiary (G)

Department of Biotechnology, Centre for Emerging Disease, Jaypee Institute of Information Technology, Noida, India.

Radhika Chadha (R)

Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH